Main content area

Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells

Yang, Jianhong, Wu, Wenshuang, Wen, Jiaolin, Ye, Haoyu, Luo, Hong, Bai, Peng, Tang, Minghai, Wang, Fang, Zheng, Li, Yang, Shengyong, Li, Weimin, Peng, Aihua, Yang, Li, Wan, Li, Chen, Lijuan
Biomaterials 2017
Food and Drug Administration, Magnolia officinalis, antineoplastic activity, apoptosis, autophagy, clinical trials, endoplasmic reticulum, honokiol, lung neoplasms, models, molecular biology, mutants, neoplasm cells, proteasome endopeptidase complex, protective effect, protein degradation, proteins, small interfering RNA, China
Honokiol (HK), a natural chemical isolated from Mangnolia officinalis, has shown antitumorigenic activities when used to treat a variety of tumor cell lines. The mechanism of honokiol activity when used to treat gefitinib-sensitive and gefitinib-resistant non-small cell lung cancer (NSCLC) requires elucidation. Here, the presence of liposomal honokiol (LHK) induced apoptotic and antitumor activities in four xenograft models generated using NSCLC cell lines such as HCC827 (gefitinib-sensitive) and H1975 (gefitinib-resistant). Mechanistic studies revealed that LHK inhibited the Akt and Erk1/2, both EGFR signaling cascades effectors, by promoting degradation of HSP90 client proteins (HCP), including wild-type or mutant EGFR, Akt and C-Raf. Molecular biology assays showed that LHK induced HCP degradation through a lysosomal pathway, rather than the canonical proteasome protein degradation pathway. As a result of misfolded protein accumulation, LHK induced endoplasmic reticulum (ER) stress and autophagy. Inhibition of ER stress (with 4-phenylbutyrate) or autophagy (with small interfering RNA) reduced LHK-induced HCP degradations. Additionally, LHK induced autophagy showed a protective role for cancer cell as inhibition of autophagy in vitro and in vivo by autophagosome degradation inhibitors could promote the anticancer activity of LHK. LHK has been approved by the China Food and Drug Administration for first-in-human clinical trials in NSCLC. The current study will guide the design of future LHK clinical trials.